EUVIMEDEUVIMED entdecken
Crossref

Repurposing of FDA‐Approved Drugs Against Leukemia by Targeting hDus2

Anshuman Chandra, Monika Mukhija, Kanika Devi, Susmita Chaudhuri, Paras Nath Yadav, Vijay Kumar Goel

ChemistrySelect · 2025-06 · 10 (23)

DOI: 10.1002/slct.202501638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 13.06.2025. Verfasst von Anshuman Chandra und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a major global health challenge, with an estimated 19.3 million new cases by 2025, largely due to lifestyle changes, environmental factors, and increased life expectancy. Despite advances in conventional therapies, issues such as drug resistance, systemic toxicity, and relapse continue to hinder long‐term survival rates. One underexplored molecular mechanism potentially contributing to cancer progression is the enzyme Human tRNA‐dihydrouridine synthase 2 (hDus2). hDus2 plays a pivotal role in tRNA modification by converting uridine residues to dihydrouridine, enhancing tRNA structural flexibility and translational efficiency. Elevated dihydrouridine levels in tRNA have been correlated with cancer progression, highlighting hDus2 as a potential therapeutic target. In this study, we investigated the inhibition of hDus2 as a novel strategy for cancer therapy. Using in silico techniques, we screened a library of FDA‐approved drugs against the 3D structure of hDus2. Top candidate compounds identified through virtual screening with the Glide module were further evaluated using molecular dynamics simulations. Parameters such as RMSD, RMSF, Rg, SASA, and PCA were analyzed. Additionally, binding free energy calculations were performed to validate the stability and interaction strength of the hDus2 ligand complexes. Our results identified DB09050, a cephalosporin antibiotic used for treating complicated intra‐abdominal infections, and DB00650, a folate analog, as promising hDus2 inhibitors. These findings pave the way for further development of anticancer therapeutics post‐experimental validation.

Zitieren

APA

Chandra, A., Mukhija, M., Devi, K., Chaudhuri, S., Yadav, P. N., & Goel, V. K. (2025). Repurposing of FDA‐Approved Drugs Against Leukemia by Targeting hDus2. ChemistrySelect, 10(23). https://doi.org/10.1002/slct.202501638

Vancouver

Chandra A, Mukhija M, Devi K, Chaudhuri S, Yadav PN, Goel VK. Repurposing of FDA‐Approved Drugs Against Leukemia by Targeting hDus2. ChemistrySelect. 2025;10(23). doi:10.1002/slct.202501638

BibTeX
@article{Chandra2025,
  author = {Chandra, Anshuman and Mukhija, Monika and Devi, Kanika and Chaudhuri, Susmita and Yadav, Paras Nath and Goel, Vijay Kumar},
  title = {Repurposing of FDA‐Approved Drugs Against Leukemia by Targeting hDus2},
  journal = {ChemistrySelect},
  year = {2025},
  volume = {10},
  number = {23},
  doi = {10.1002/slct.202501638}
}
Kostenlos starten →